AstraZeneca scores orphan status for PD-L1/CTLA-4 combo; EMA OKs Novartis' MS drug Mayzent
→ AstraZeneca gained an orphan drug designation for its combination of Imfinzi and the CTLA-4 drug tremelimumab for hepatocellular carcinoma …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.